Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
Tuesday, August 28, 2018 9:57:41 AM
I am getting a feeling that the review is more an attention getter for RRx-001 than a serious review - short treatment of each drug with references to some significant articles and letters not to be found. For instance: the report of GC4419 phase 1 trial in OM, criticism for both palifermin HNC trials. The article does touch the criticism of palifermin trials, but without references for their mildly strange conclusions.
It will be interesting to see how well RRx-001 protection of bone marrow will extend into protection of oral mucosa. Based on the information the authors of the review provide and with my extremely limited knowledge of biology involved, RRx-001 modified red blood cells probably will accumulate in the environment of some (dense) tumors. Bumpkin explanation: they can't get in due to collapsed tumor blood vessels so they bleed into tumor environment. But to what extent? Accumulation will probably be in much lesser numbers than in bone marrow. My opinion, not a fact, which usually makes the opposite more likely fact.
I do agree with the authors of the review that future treatment of SOM will be a combination of drugs where one will work, using Sonis model, in early initiation/oxidation stage of cell damage, the other will act on cytokines and/or other inflammatory agents and may even promote healing process. It is helluva hard to design a single, tolerable compound that would be active in all 5 stages.
"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM